In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vernalis (R&D) Ltd.

http://www.vernalis.com

Latest From Vernalis (R&D) Ltd.

Pierre Fabre Continues Oncology R&D Push

The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.

Cancer M & A

Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

The company said the “totality of data” from the confirmatory PROTECT trial in IgA nephropathy showed the drug slowed decline in kidney function.

Clinical Trials FDA

Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout

The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.

Clinical Trials Rare Diseases

Finance Watch: Big Financings Show Investors Remain Interested In Certain Opportunities

A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.

Financing Growth
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Cita NeuroPharmaceuticals
    • Vernalis Group plc
UsernamePublicRestriction

Register